Matrixx Misled Shareholders About Zicam Problems, Investors Allege
This article was originally published in The Tan Sheet
Executive Summary
Shareholders in litigation against Matrixx Initiatives pending in the U.S. Supreme Court say a reasonable person's decision on whether information about a firm is important – not a statistical significance measure – should be the standard for determining when a company must reveal problems with a product.